NasdaqGS:ARQTBiotechs
Does Positive Infant Atopic Dermatitis Data Alter The Bull Case For Arcutis Biotherapeutics’ ZORYVE (ARQT)?
On March 28, 2026, Arcutis Biotherapeutics presented new Phase 2 INTEGUMENT-INFANT data at the American Academy of Dermatology meeting, showing ZORYVE (roflumilast) cream 0.05% was well tolerated and improved skin clearance in infants aged 3 to 24 months with mild to moderate atopic dermatitis.
This positive pediatric dataset underpins Arcutis’s plan to file a supplemental FDA application in the second quarter of 2026, potentially broadening ZORYVE’s reach into very young patients.
Next,...